MOESM1 of Glitazones and alpha-glucosidase inhibitors as the second-line oral anti-diabetic agents added to metformin reduce cardiovascular risk in Type 2 diabetes patients: a nationwide cohort observational study

Autor: Chan, Cheng-Wei, Yu, Chu-Leng, Lin, Jiunn-Cherng, Hsieh, Yu-Cheng, Lin, Che-Chen, Hung, Chen-Ying, Li, Cheng-Hung, Liao, Ying-Chieh, Lo, Chu-Pin, Huang, Jin-Long, Lin, Ching-Heng, Wu, Tsu-Juey
Rok vydání: 2018
Předmět:
DOI: 10.6084/m9.figshare.5821893.v1
Popis: Additional file 1: Table S1. Hazard ratios of MACE in patients receiving different 2nd-line anti-diabetic agents with or without ACEI/ARBs and statins. Table S2. Hazard ratios of MACE in patients receiving pioglitazone and rosiglitazone as the 2nd-line anti-diabetic agents compared to SU.
Databáze: OpenAIRE